J.B. Chemicals & Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹4,148cr+5.9% on FY25
EBITDA: ₹1,107cr+7.3% on FY25
Net profit: ₹709cr+7.6% on FY25
EPS: ₹45.16+6.4% on FY25

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	4,148	3,918	3,484	3,149	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	60.2	38.3	37.3	9.9
	4,208	3,956	3,521	3,159
	912	820	816	784
	478	497	413	395
	−94.1	−0.4	−46.9	−11.0
	773	688	601	543
	5.6	11.7	44.3	36.1
	183	171	138	114
	971	882	804	742
	3,228	3,069	2,770	2,604
	1,107	1,032	897	696
	925	861	759	581
Profit
	980	887	752	555
	−27.2	0.0	0.0	0.0
	952	887	752	555
	232	200	151	89.3
	10.6	27.4	47.9	55.9
	243	228	199	145
	709	660	553	410
	709	660	553	410
	26.8	8.5	−14.6	−13.6
	736	668	538	396
	709	660	553	410
	0.0	0.0	0.0	0.2
Per share
	₹45.16	₹42.45	₹35.66	₹53.00
	₹44.45	₹41.56	₹34.85	₹52.34
Other comprehensive income — detail
	26.8	8.5	—	—
	−3.6	−5.9	−5.0	0.2
	−0.9	−1.5	—	—
	—	—	−1.3	0.0
	29.3	13.6	−11.5	−13.9
	−0.2	0.6	—	—
	—	—	−0.6	−0.2
	736	668	538	397
	0.0	0.0	0.0	−0.2
Per share — as-filed variants
	₹45.16	₹42.45	₹35.66	₹53.00
	₹44.45	₹41.56	₹34.85	₹52.34
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,852	2,601	2,302	1,981
	68.7%	66.4%	66.1%	62.9%
Adjusted (ex-exceptional items) — derived
	980	887	752	555
	−27.2	0.0	0.0	0.0
	730	660	553	410
	₹46.45	₹42.45	₹35.66	₹53.00

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersTORNTPHARM ALKEM IPCALAB SAILIFE NH NEULANDLAB ACUTAAS NATCOPHARM

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Revenue from Operations	3,149.3	3,484.2	3,918.0	4,147.8
Other Income	9.9	37.3	38.3	60.2
Total Income	3,159.2	3,521.5	3,956.3	4,207.9
Expenses
+ Cost of Materials Consumed	784.0	816.3	820.0	912.4
+ Purchases of Stock-in-Trade	395.2	412.6	497.0	477.9
+ Changes in Inventories	-11.0	-46.9	-0.4	-94.1
+ Employee Benefit Expense	543.5	601.4	687.6	772.7
+ Finance Costs	36.1	44.3	11.7	5.6
+ Depreciation & Amortisation	114.4	138.3	171.0	182.5
+ Other Expenses	741.9	803.8	882.0	971.4
Total Expenses	2,604.0	2,769.9	3,068.9	3,228.4
EBITDA	695.8	896.9	1,031.8	1,107.4
EBIT	581.3	758.6	860.8	924.9
Profit
PBT before Exceptional Items	555.2	751.5	887.4	979.5
+ Exceptional Items	0.0	0.0	0.0	-27.2
Pretax Income	555.2	751.5	887.4	952.3
+ Current Tax	89.3	151.0	200.4	232.3
+ Deferred Tax	55.9	47.9	27.4	10.6
Tax Expense	145.2	198.9	227.8	242.9
Net Income	410.0	552.6	659.6	709.5
+ Net Income — Continuing Ops	410.0	552.6	659.6	709.5
+ Other Comprehensive Income	-13.6	-14.6	8.5	26.8
Total Comprehensive Income	396.4	538.0	668.1	736.2
Net Income to Common	409.8	552.6	659.6	709.5
Minority Interest	0.2	0.0	0.0	0.0
Per Share
Basic EPS	53.00	35.66	42.45	45.16
Diluted EPS	52.34	34.85	41.56	44.45
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	8.5	26.8
+ Items NOT to be Reclassified to P&L	0.2	-5.0	-5.9	-3.6
+ Tax on Items NOT to be Reclassified	—	—	-1.5	-0.9
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-1.3	—	—
+ Items to be Reclassified to P&L	-13.9	-11.5	13.6	29.3
+ Tax on Items to be Reclassified	—	—	0.6	-0.2
+ Tax on Items to be Reclassified — alt tag	-0.2	-0.6	—	—
Comprehensive Income — Owners of Parent	396.6	538.0	668.1	736.2
Comprehensive Income — Non-controlling Interests	-0.2	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	53.00	35.66	42.45	45.16
Diluted EPS — Continuing Operations	52.34	34.85	41.56	44.45
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,981.1	2,302.1	2,601.4	2,851.5
Gross Margin %	62.91	66.07	66.40	68.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	555.2	751.5	887.4	979.5
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-27.2
Net Income Adj (tax-effected)	410.0	552.6	659.6	729.7
EPS Adj	53.00	35.66	42.45	46.45
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	1.00	1.00	1.00
Paid Up Equity Capital	15.5	15.5	15.6	16.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.